<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use another method of contraception, in particular a barrier type, during the length of time that these are administered together and one cycle after.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another reliable contraceptive method, in particular a barrier type, should be used during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy) </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampanel &gt;=12 mg/day: Risk of decrease of the contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not restart the progestin contraceptive treatment fewer than 12 days after stopping the ulipristal.</COMMENT>
</INTERACTION>
</INTERACTIONS>
